The financial impact of the COVID-19 pandemic presents a potential risk to the future of clinical trials in rare diseases. Rare diseases by their nature are not very prevalent in the population, therefore, any treatment for a rare disease will only have a small number of beneficiaries. In addition, so-called orphan drug development takes around 18% […]
As COVID-19 continues to spread across the U.S., its impact on the U.S. health system is without precedent, with direct and indirect medical costs estimated to be in the hundreds of billions of dollars. On an individual basis, cost estimates from the Peterson Center on Healthcare and Kaiser Family Foundation (KFF) range from between $10,000 to […]
Many companies, particularly new entrants into the U.S. pharma arena, are facing some level of disruption or impact on their projected timelines for seeking FDA licensure, gathering data from trials for filing, conducting health economics analyses needed to demonstrate improved outcomes, or conducting real-world evidence studies that can help inform medical societies’ deliberations on clinical […]
When can Canadians expect a vaccine for COVID-19? Watch to learn more about why Dr. Kelvin is “cautiously optimistic” about where we stand.
COVID-19 has had a fundamental effect on every aspect of society, including clinical trials. The search for an effective vaccine or treatment for COVID-19 continues to move at record pace. However, many clinical trials in other therapeutic areas have either been delayed or essentially ground to a halt due to the pandemic. Such delays place […]
The availability of data, experts for authoring abstracts, posters and oral presentations, and congress activities themselves have all been affected by the pandemic.
Clinical trials are the engine room that powers our ability to deliver new treatment options to patients. The rigorous testing and resulting data that help us understand how new treatments work are what propels our industry forward.
We have seen a digital revolution sweep across clinical practice, driven by the extraordinary circumstances of the coronavirus.
With reduced capacity and opportunity for fundraising, extra pressure on support services and attention diverted elsewhere, it will take a long time for them to recover and return to business as usual.
While initial impressions may be that the COVID-19 pandemic is creating a barrier for medical education initiatives, this is not necessarily the case across the board.